文献速递胃肠外科

Senhance数字腹腔镜系统与腹腔镜结肠切除术短期与中期结局的倾向性评分匹配研究

Comparison of short- and mid-term outcomes between the Senhance digital laparoscopic system and laparoscopic colectomy: a propensity score matching study.
PubMed 文献 · Surg Endosc · 2024-12-23

本研究比较Senhance辅助结肠切除术与腹腔镜结肠切除术的短期和中期结局。倾向性评分匹配后每组47例,Senhance组手术时间显著更长(240分钟 vs 191分钟,p<0.01),两组术后并发症及3年无病生存率、总生存率无显著差异。结论认为Senhance辅助结肠切除术安全,中期结局与腹腔镜相当,但手术时间延长仍需进一步研究。

要点

  • Senhance辅助结肠切除术安全,中期肿瘤学结局与腹腔镜相当。
  • Senhance组手术时间显著长于腹腔镜组。
  • 两组术后并发症及生存率无显著差异。

核心结论

  • Senhance辅助结肠切除术安全,中期结局与腹腔镜手术相当。
  • 手术时间延长仍是挑战,需随机对照试验和多中心研究验证。

研究设计与样本

  • 采用1:1倾向性评分匹配,调整性别、年龄、肿瘤位置、BMI、ASA-PS、cT和cN等协变量。
  • 比较50例Senhance辅助结肠切除术与430例腹腔镜结肠切除术,匹配后每组47例。

主要发现

  • Senhance组手术时间显著长于腹腔镜组(中位数240分钟 vs 191分钟,p<0.01)。
  • 术后30天内Clavien-Dindo 2级及以上并发症无显著差异,未报告机器人相关不良事件。
  • 3年无病生存率Senhance组88.7%,腹腔镜组77.1%(p=0.178;HR=1.423;95%CI 0.916-2.211)。
  • 总生存率两组均为97.7%(p=0.897;HR=1.202;95%CI 0.075-19.26)。

临床怎么用

  • Senhance辅助结肠切除术可作为腹腔镜结肠切除术的可行替代,但需考虑手术时间延长。
  • 中期肿瘤学结局与腹腔镜相当,支持其安全性。

局限性

  • 回顾性研究设计,样本量较小(匹配后每组47例)。
  • 需要随机对照试验和多中心研究进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Senhance digital laparoscopic system (Senhance) is a surgical robot approved for use in Japan after the da Vinci system. Our institution was the first to introduce this system, which has been used primarily for gastrointestinal surgery. Featuring tactile feedback, eye-movement-controlled camera operation, stereoscopic vision, and magnification, the short-term postoperative outcomes of the Senhance in abdominal surgery have been documented. This study aimed to evaluate the safety and feasibility of Senhance by examining mid-term postoperative outcomes. METHODS: Between January 2018 and December 2020, 743 patients underwent colorectal cancer colectomy at our institution. We compared 50 cases of Senhance-assisted colectomy with 430 laparoscopic colectomy cases using 1:1 propensity score matching, adjusting for covariates such as sex, age, tumor location, BMI, ASA-PS, cT, and cN. Short- and mid-term surgical outcomes were compared between the Senhance (S) and laparoscopic (L) groups. RESULTS: After matching, 47 patients were included in each group. There were no significant differences in the patient backgrounds. The operative time was significantly longer in the S group compared to the L group (median: 240 [101-378] minutes vs. 191 [100-370] minutes, p < 0.01). No significant differences were observed in postoperative complications of Clavien-Dindo grade 2 or higher within 30 days post-surgery, and no robot-related adverse events were reported. The 3-year disease-free survival rates were 88.7% in the S group and 77.1% in the L group (p = 0.178; HR, 1.423; 95% CI 0.916-2.211). The overall survival rate was 97.7% in both groups (p = 0.897; HR, 1.202; 95% CI 0.075-19.26). CONCLUSION: Senhance-assisted colectomy is safe with mid-term outcomes comparable to laparoscopic surgery. However, the extended operation time remains challenging, necessitating further studies, including randomized controlled trials and multicenter studies, to validate these findings.

来源:Surg Endosc,查看原文。版权归原作者所有。

引用

  1. Fujii T, Hirano Y, Ishiyama Y, et al. Comparison of short- and mid-term outcomes between the Senhance digital laparoscopic system and laparoscopic colectomy: a propensity score matching study. Surg Endosc. 2024. PMID: 39715957. doi:10.1007/s00464-024-11482-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。